Reports Q3 revenue $334.2M, consensus $328.67M. The company said, “Not only are we growing at an incredible rate, reaching positive adjusted EBITDA marks an important milestone and reflects the strength of our underlying business. One of the hardest things to do, and a sign of business model endurance, is being able to slow down the rate of reinvesting back into the business and still maintain growth, which is exactly what we achieved this quarter.”
Claim 30% Off TipRanks
Trade TEM with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI’s Strategic Collaboration with Whitehawk Therapeutics Bolsters Buy Rating with Promising Oncology Advances
- Cathie Wood Trims Exposure to AMD and Other U.S. Tech Favorites, Doubles Down on Baidu and Biotech Plays
- Guardant Health price target raised to $90 from $60 at Piper Sandler
- Tempus AI price target raised to $105 from $70 at Piper Sandler
- Goldman downgraded, Coinbase initiated: Wall Street’s top analyst calls